Response of triple negative breast cancer to BAZ2A/B inhibition and BET bromodomain inhibition alone and in combination (ChIPseq)
收藏NIAID Data Ecosystem2026-04-25 收录
下载链接：
https://www.ncbi.nlm.nih.gov/sra/SRP152992
下载链接
链接失效反馈官方服务：
资源简介：
Three triple negative breast cancer cell lines (MDAMB231, SUM159, and HCC1806) were treated with small molecule inhibitors (JQ1, BET bromodomain inhibitor; GSK2801, BAZ2A/B bromodomain inhibitor) or BAZ siRNA alone and in combination with JQ1 for 48 hours Overall design: 34 experimental samples analyzed, 2 chromatin input control samples
创建时间：
2019-10-09
